000			03474nam a2200445 i 4500
999			_c360932 _d360932
001			360932
003			ES-MaUEC
005			20230102121300.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			210325s2021 sz a s |||| 0|eng d
020			_a9783030700638
024	7		_a10.1007/978-3-030-70063-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM301.25 _b2021 EB
245	0	0	_aOrganotypic Models in Drug Development _cedited by Monika Schäfer-Korting, Silvya Stuchi Maria-Engler, Robert Landsiedel
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
264		4	_c2021
300			_a1 recurso en línea (VIII, 323 páginas) _b70 ilustraciones, 37 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
490	0		_aHandbook of Experimental Pharmacology _x1865-0325 _v265
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_aInflammatory skin disease models in vitro and in animals - predictability for drug development -- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System -- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development -- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh -- Disease Models: Lung models for testing drugs against inflammation and infection -- In Vitro Models of the Blood-Brain Barrier -- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development -- The CAM Assay as an Alternative In Vivo Model for Drug Testing -- Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development -- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling -- Immunocompetent human intestinal models in preclinical drug development -- Engineered Heart Muscle Models in Phenotypic Drug Screens.
520	3		_aThis book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _aFarmacología _9137893
700	1		_aSchäfer-Korting, Monika. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aStuchi Maria-Engler, Silvya. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aLandsiedel, Robert. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030700621
776	0	8	_iPrinted edition: _z9783030700645
776	0	8	_iPrinted edition: _z9783030700652
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-70063-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _ek _zSI